<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01103323</url>
  </required_header>
  <id_info>
    <org_study_id>14387</org_study_id>
    <secondary_id>2009-012787-14</secondary_id>
    <nct_id>NCT01103323</nct_id>
  </id_info>
  <brief_title>Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled multi-center phase III study to
      evaluate efficacy and safety of regorafenib in patients with metastatic colorectal cancer
      (CRC) who have progressed on/after all approved drugs for CRC
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All participants received Best Supportive Care. Acronyms used in Adverse events section:
      Gastrointestinal (GI), Genitourinary (GU), Not Otherwise Specified (NOS), Absolute Neutrophil
      Count (ANC), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Common
      Terminology Criteria for Adverse Events (CTCAE), International Normalized Ratio (INR),
      Central nervous system (CNS), Acute respiratory distress syndrome (ARDS), Cranial nerves
      (CN), Disseminated Intravascular Coagulation (DIC), Cardiac troponin T (cTnT).

      Abbreviation used in Results section: Data Monitoring Committee (DMC). Adverse event
      collection will be covered in Adverse events section.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis (IA).</time_frame>
    <description>Overall survival (OS) was defined as the time (days) from randomization to death due to any cause. Patients alive at the time of analysis were censored at the last date known to be alive. If a patient was lost to follow-up and there was no contact after randomization, this patient was censored at Day 1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (Based on Investigator's Assessment)</measure>
    <time_frame>From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis. Tumor assessed at 8 week intervals.</time_frame>
    <description>Progression-free survival was defined as the time (days) from date of randomization to date of first observed disease progression (radiological or clinical) or death due to any cause, if death occurred before progression was documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Tumor Response</measure>
    <time_frame>From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis. Tumor assessed at 8 week intervals.</time_frame>
    <description>The objective tumor response was defined as the percentage of patients with complete response (CR, tumor disappears) or partial response (PR, sum of lesion sizes decreased at least 30% from baseline) as best overall response. A best overall response was defined for all patients, using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1. Patients whose best overall response was not CR or PR, and any patients with no post-baseline assessments were considered nonresponders for the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control</measure>
    <time_frame>From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis. Tumor assessed at 8 week intervals.</time_frame>
    <description>Disease control was defined as the percentage of patients whose best response was not PD [sum of lesion sizes increased at least 20% from smallest sum on study or new lesions] (ie, CR [tumor disappears], PR [sum of lesion sizes decreased at least 30% from baseline] or SD (stable disease)). SD included if at least 6 weeks after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Response</measure>
    <time_frame>From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis. Tumor assessed at 8 week intervals.</time_frame>
    <description>A tumor response (best overall response) was defined for all patients, using the RECIST criteria, version 1.1. Categories: complete response (CR, tumor disappears), partial response (PR, sum of lesion sizes decreased at least 30% from baseline), stable disease (SD, steady state of disease), progressive disease (PD, sum of lesion sizes increased at least 20% from smallest sum on study or new lesions). Clinical PD considered when radiographic imaging not possible.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">760</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Regorafenib (Stivarga, BAY73-4506)+BSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received Regorafenib 160 mg per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus Best Supportive Care(BSC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+BSC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received matching placebo tablets per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus Best Supportive Care (BSC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib (Stivarga, BAY73-4506)</intervention_name>
    <description>160 mg per oral once daily for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)</description>
    <arm_group_label>Regorafenib (Stivarga, BAY73-4506)+BSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching placebo tablets for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)</description>
    <arm_group_label>Placebo+BSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Supportive Care (BSC)</intervention_name>
    <description>BSC includes any concomitant medications or treatments: antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy necessary to provide BSC, except other investigational anti-tumor agents or anti-neoplastic chemo/hormonal/immuno-therapy.</description>
    <arm_group_label>Regorafenib (Stivarga, BAY73-4506)+BSC</arm_group_label>
    <arm_group_label>Placebo+BSC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological documentation of adenocarcinoma of the colon or rectum

          -  Progression during or within 3 months following the last administration of approved
             standard therapies. Patients treated with oxaliplatin in an adjuvant setting should
             have progressed during or within 6 months of completion of adjuvant therapy

          -  Patients with measurable or non measurable disease

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of &lt;/= 1

          -  Life expectancy of at least 3 months

          -  Adequate bone marrow, liver and renal function

        Exclusion Criteria:

          -  Unstable/uncontrolled cardiac disease

          -  History of arterial or venous thrombotic or embolic events

          -  Symptomatic metastatic brain or meningeal tumors

          -  Patients with evidence or history of bleeding diathesis

          -  Interstitial lung disease - Persistent proteinuria &gt;/= grade 3

          -  Unresolved toxicity &gt; grade 1 attributed to any prior therapy/procedure excluding
             alopecia and oxaliplatin induced neurotoxicity &lt;/= Grade 2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615-7828</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cedar Rapids</city>
        <state>Iowa</state>
        <zip>52403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Cloud</city>
        <state>Minnesota</state>
        <zip>56303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <zip>65109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07754</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scranton</city>
        <state>Pennsylvania</state>
        <zip>18510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sumter</city>
        <state>South Carolina</state>
        <zip>29150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <state>Ciudad Auton. de Buenos Aires</state>
        <zip>C1122AAL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <state>Ciudad Auton. de Buenos Aires</state>
        <zip>C1264AAA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000PBJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Miguel de Tucumán</city>
        <state>Tucuman</state>
        <zip>T4000GTB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Capital Federal-Buenos Aires</city>
        <zip>C1426ANZ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woolloogabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woodville South</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Footscray</city>
        <state>Victoria</state>
        <zip>3011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles - Brussel</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles - Brussel</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles - Brussel</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>41830-492</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fortaleza</city>
        <state>Ceará</state>
        <zip>60160-230</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30110-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ijuí</city>
        <state>Rio Grande do Sul</state>
        <zip>98700-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266100</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Changchun</city>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chongqing</city>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chongqing</city>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fuzhou</city>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fuzhou</city>
        <zip>350025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ha'erbin</city>
        <zip>150040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hanghzou</city>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tianjin</city>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <zip>65 653</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha</city>
        <zip>18081</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Le Mans Cedex 2</city>
        <zip>72015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille Cedex</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Strasbourg Cedex</city>
        <zip>67085</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Karlsruhe</city>
        <state>Baden-Württemberg</state>
        <zip>76137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mannheim</city>
        <state>Baden-Württemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Württemberg</state>
        <zip>70199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81737</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81925</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oldenburg</city>
        <state>Niedersachsen</state>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leverkusen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51375</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porta Westfalica</city>
        <state>Nordrhein-Westfalen</state>
        <zip>32457</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trier</city>
        <state>Rheinland-Pfalz</state>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halle</city>
        <state>Sachsen-Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1082</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ashkelon</city>
        <zip>7830604</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beer Sheva</city>
        <zip>8410101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petach Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rehovot</city>
        <zip>7610001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Hashomer</city>
        <zip>5262000</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zrifin</city>
        <zip>6093000</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brescia</city>
        <zip>25124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osakasayama</city>
        <state>Osaka</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <zip>569-8686</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hidaka</city>
        <state>Saitama</state>
        <zip>350-1298</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kita-Adachigun</city>
        <state>Saitama</state>
        <zip>362-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sunto</city>
        <state>Shizuoka</state>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shimotsuke</city>
        <state>Tochigi</state>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Utsunomiya</city>
        <state>Tochigi</state>
        <zip>320-0834</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mitaka</city>
        <state>Tokyo</state>
        <zip>181-8611</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiba</city>
        <zip>260-8717</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kochi</city>
        <zip>781-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <zip>540-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hoofddorp</city>
        <zip>2134 TM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leeuwarden</city>
        <zip>8901 BR</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aveiro</city>
        <zip>3810-096</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coimbra</city>
        <zip>3030-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto</city>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chur</city>
        <state>Graubünden</state>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genève</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ankara</city>
        <zip>06500</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Instanbul</city>
        <zip>34662</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Istanbul</city>
        <zip>34390</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.clinicaltrialsregister.eu/</url>
    <description>Click here to find information about studies related to Bayer Healthcare products conducted in Europe</description>
  </link>
  <results_reference>
    <citation>Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26;381(9863):303-12. doi: 10.1016/S0140-6736(12)61900-X. Epub 2012 Nov 22.</citation>
    <PMID>23177514</PMID>
  </results_reference>
  <results_reference>
    <citation>Mross K, Frost A, Steinbild S, Hedbom S, Büchert M, Fasol U, Unger C, Krätzschmar J, Heinig R, Boix O, Christensen O. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012 May 1;18(9):2658-67. doi: 10.1158/1078-0432.CCR-11-1900. Epub 2012 Mar 15.</citation>
    <PMID>22421192</PMID>
  </results_reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2010</study_first_submitted>
  <study_first_submitted_qc>April 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2010</study_first_posted>
  <results_first_submitted>October 19, 2012</results_first_submitted>
  <results_first_submitted_qc>October 19, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 19, 2012</results_first_posted>
  <last_update_submitted>May 28, 2015</last_update_submitted>
  <last_update_submitted_qc>May 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Colorectal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Regorafenib (Stivarga, BAY73-4506)+BSC</title>
          <description>Participants received Regorafenib 160 mg per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus best supportive care (BSC).</description>
        </group>
        <group group_id="P2">
          <title>Placebo+BSC</title>
          <description>Participants received matching placebo tablets per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus best supportive care (BSC). Period 1 is placebo and placebo-regorafenib with placebo period only before unblinding. Period 2 is placebo-regorafenib with regorafenib period only.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Without/Before Drug Switch</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="505"/>
                <participants group_id="P2" count="255"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="500"/>
                <participants group_id="P2" count="253"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="429"/>
                <participants group_id="P2" count="237"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>did not receive study treatment</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Switch to Regorafenib</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Switched From Placebo to Regorafenib</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4">Participants in the placebo+BSC group switched to Regorafenib treatment after unblinding.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Regorafenib (Stivarga, BAY73-4506)+BSC</title>
          <description>Participants received Regorafenib 160 mg per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus best supportive care (BSC).</description>
        </group>
        <group group_id="B2">
          <title>Placebo+BSC</title>
          <description>Participants received matching placebo tablets per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus best supportive care (BSC).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="505"/>
            <count group_id="B2" value="255"/>
            <count group_id="B3" value="760"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>The age of the patient in years at enrollment in the study.</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.7" lower_limit="22" upper_limit="82"/>
                    <measurement group_id="B2" value="60.1" lower_limit="25" upper_limit="85"/>
                    <measurement group_id="B3" value="60.5" lower_limit="22" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="194"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="311"/>
                    <measurement group_id="B2" value="153"/>
                    <measurement group_id="B3" value="464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG) performance status (PS) before treatment</title>
          <description>ECOG PS is a scale that measures how cancer affects the daily life of a patient on an ordinal scale from grade 0 (best) to grade 5 (worst). 0=Fully active without restriction; 1= Restricted in physically strenuous activity; 2= Ambulatory, capable of all selfcare; 3= Capable of limited selfcare; 4= Completely disabled; 5= Dead</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="265"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="240"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>KRAS mutation</title>
          <description>KRAS - Kirsten rat sarcoma viral oncogene homolog (protein), member of the RAS family of GTPases (guanosine triphosphate hydrolases)</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="205"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="273"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Overall survival (OS) was defined as the time (days) from randomization to death due to any cause. Patients alive at the time of analysis were censored at the last date known to be alive. If a patient was lost to follow-up and there was no contact after randomization, this patient was censored at Day 1.</description>
        <time_frame>From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis (IA).</time_frame>
        <population>Intent to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Regorafenib (Stivarga, BAY73-4506)+BSC</title>
            <description>Participants received Regorafenib 160 mg per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus best supportive care (BSC).</description>
          </group>
          <group group_id="O2">
            <title>Placebo+BSC</title>
            <description>Participants received matching placebo tablets per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus best supportive care (BSC)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival (OS) was defined as the time (days) from randomization to death due to any cause. Patients alive at the time of analysis were censored at the last date known to be alive. If a patient was lost to follow-up and there was no contact after randomization, this patient was censored at Day 1.</description>
          <population>Intent to treat (ITT)</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="505"/>
                <count group_id="O2" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196" lower_limit="178" upper_limit="222"/>
                    <measurement group_id="O2" value="151" lower_limit="134" upper_limit="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sample size based on primary efficacy endpoint of OS. The study was designed to have 90% power to detect 33.3% increase in median OS (i.e. hazard ratio of 0.75, Regorafenib / Placebo). Assuming 1-sided overall alpha of 0.025, randomization ratio of 2:1 for Regorafenib and Placebo, and 2 formal interim analyses of OS using an O’Brien-Fleming-type error spending function, a total of 582 death events were required for primary completion. Results based on 2nd planned formal IA with 432 total events.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005178</p_value>
            <p_value_desc>According to protocol specified O'Brien-Fleming type alpha spending function and 432 death events at 2nd IA, the pre-specified alpha (false positive rate) for this analysis was 0.009279 (1-sided).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.774</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.636</ci_lower_limit>
            <ci_upper_limit>0.942</ci_upper_limit>
            <estimate_desc>Two treatment groups compared using a stratified log-rank test, stratified by same stratification factors as randomization. Hazard ratio (Regorafenib / Placebo) and its 95% confidence interval calculated using Cox model, stratified by same factors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (Based on Investigator’s Assessment)</title>
        <description>Progression-free survival was defined as the time (days) from date of randomization to date of first observed disease progression (radiological or clinical) or death due to any cause, if death occurred before progression was documented.</description>
        <time_frame>From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis. Tumor assessed at 8 week intervals.</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Regorafenib (Stivarga, BAY73-4506)+BSC</title>
            <description>Participants received Regorafenib 160 mg per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus best supportive care (BSC).</description>
          </group>
          <group group_id="O2">
            <title>Placebo+BSC</title>
            <description>Participants received matching placebo tablets per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus best supportive care (BSC)</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (Based on Investigator’s Assessment)</title>
          <description>Progression-free survival was defined as the time (days) from date of randomization to date of first observed disease progression (radiological or clinical) or death due to any cause, if death occurred before progression was documented.</description>
          <population>ITT</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="505"/>
                <count group_id="O2" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" lower_limit="57" upper_limit="65"/>
                    <measurement group_id="O2" value="52" lower_limit="51" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Two treatment groups compared using a stratified log-rank test, stratified by same stratification factors as randomization. Hazard ratio (Regorafenib / Placebo) and its 95% confidence interval calculated using Cox model, stratified by same factors.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.000001</p_value>
            <p_value_desc>Comparison based on pre-specified alpha level of 0.025 (1-sided).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.494</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.419</ci_lower_limit>
            <ci_upper_limit>0.582</ci_upper_limit>
            <estimate_desc>Hazard ratio (Regorafenib / Placebo)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Tumor Response</title>
        <description>The objective tumor response was defined as the percentage of patients with complete response (CR, tumor disappears) or partial response (PR, sum of lesion sizes decreased at least 30% from baseline) as best overall response. A best overall response was defined for all patients, using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1. Patients whose best overall response was not CR or PR, and any patients with no post-baseline assessments were considered nonresponders for the analysis.</description>
        <time_frame>From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis. Tumor assessed at 8 week intervals.</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Regorafenib (Stivarga, BAY73-4506)+BSC</title>
            <description>Participants received Regorafenib 160 mg per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus best supportive care (BSC).</description>
          </group>
          <group group_id="O2">
            <title>Placebo+BSC</title>
            <description>Participants received matching placebo tablets per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus best supportive care (BSC)</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Tumor Response</title>
          <description>The objective tumor response was defined as the percentage of patients with complete response (CR, tumor disappears) or partial response (PR, sum of lesion sizes decreased at least 30% from baseline) as best overall response. A best overall response was defined for all patients, using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1. Patients whose best overall response was not CR or PR, and any patients with no post-baseline assessments were considered nonresponders for the analysis.</description>
          <population>ITT</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="505"/>
                <count group_id="O2" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Two treatment groups compared using Cochran-Mantel-Haenszel (CMH) test adjusting for same stratification factors as at randomization.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.188432</p_value>
            <p_value_desc>Comparison based on pre-specified alpha level of 0.025 (1-sided).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference</param_type>
            <param_value>-0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.74</ci_lower_limit>
            <ci_upper_limit>0.53</ci_upper_limit>
            <estimate_desc>Difference = Placebo - Regorafenib 160 mg</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control</title>
        <description>Disease control was defined as the percentage of patients whose best response was not PD [sum of lesion sizes increased at least 20% from smallest sum on study or new lesions] (ie, CR [tumor disappears], PR [sum of lesion sizes decreased at least 30% from baseline] or SD (stable disease)). SD included if at least 6 weeks after randomization.</description>
        <time_frame>From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis. Tumor assessed at 8 week intervals.</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Regorafenib (Stivarga, BAY73-4506)+BSC</title>
            <description>Participants received Regorafenib 160 mg per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus best supportive care (BSC).</description>
          </group>
          <group group_id="O2">
            <title>Placebo+BSC</title>
            <description>Participants received matching placebo tablets per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus best supportive care (BSC)</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control</title>
          <description>Disease control was defined as the percentage of patients whose best response was not PD [sum of lesion sizes increased at least 20% from smallest sum on study or new lesions] (ie, CR [tumor disappears], PR [sum of lesion sizes decreased at least 30% from baseline] or SD (stable disease)). SD included if at least 6 weeks after randomization.</description>
          <population>ITT</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="505"/>
                <count group_id="O2" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0"/>
                    <measurement group_id="O2" value="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Two treatment groups compared using Cochran-Mantel-Haenszel (CMH) test adjusting for same stratification factors as at randomization.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.000001</p_value>
            <p_value_desc>Comparison based on pre-specified alpha level of 0.025 (1-sided).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference</param_type>
            <param_value>-25.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-32.06</ci_lower_limit>
            <ci_upper_limit>-19.82</ci_upper_limit>
            <estimate_desc>Difference = Placebo - Regorafenib 160 mg</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Response</title>
        <description>A tumor response (best overall response) was defined for all patients, using the RECIST criteria, version 1.1. Categories: complete response (CR, tumor disappears), partial response (PR, sum of lesion sizes decreased at least 30% from baseline), stable disease (SD, steady state of disease), progressive disease (PD, sum of lesion sizes increased at least 20% from smallest sum on study or new lesions). Clinical PD considered when radiographic imaging not possible.</description>
        <time_frame>From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis. Tumor assessed at 8 week intervals.</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Regorafenib (Stivarga, BAY73-4506)+BSC</title>
            <description>Participants received Regorafenib 160 mg per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus best supportive care (BSC).</description>
          </group>
          <group group_id="O2">
            <title>Placebo+BSC</title>
            <description>Participants received matching placebo tablets per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus best supportive care (BSC)</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Response</title>
          <description>A tumor response (best overall response) was defined for all patients, using the RECIST criteria, version 1.1. Categories: complete response (CR, tumor disappears), partial response (PR, sum of lesion sizes decreased at least 30% from baseline), stable disease (SD, steady state of disease), progressive disease (PD, sum of lesion sizes increased at least 20% from smallest sum on study or new lesions). Clinical PD considered when radiographic imaging not possible.</description>
          <population>ITT</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="505"/>
                <count group_id="O2" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.8"/>
                    <measurement group_id="O2" value="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease (PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.5"/>
                    <measurement group_id="O2" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non CR/Non PD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not applicable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not assessed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7"/>
                    <measurement group_id="O2" value="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AE was collected up to 30 days after end of study treatment (per protocol) over a period of approximately 3.7 years.</time_frame>
      <desc>Disseminated Intravascular Coagulation (DIC), International Normalized Ratio (INR), Cardiac Troponin T (cTnT), Gastroihntestina (GI), Not Otherwise Specified (NOS), Aspartate Aminotransferase (AST), Genitourinary (GU), Alanine Aminotransferase (ALT), Acute Respiratory Distress Syndrome (ARDS), Absolute Neutrophil Count (ANC)</desc>
      <group_list>
        <group group_id="E1">
          <title>Regorafenib (BAY73-4506)+BSC</title>
          <description>Participants received Regorafenib 160 mg per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus best supportive care (BSC).</description>
        </group>
        <group group_id="E2">
          <title>Placebo+BSC</title>
          <description>Participants received matching placebo tablets per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus best supportive care (BSC). It is for placebo period only before unblinding.</description>
        </group>
        <group group_id="E3">
          <title>Placebo - Regorafenib After Unblinding</title>
          <description>Participants in the placebo+BSC group switched to treatment with Regorafenib after unblinding. It is for Regorafenib treatment period only</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI-CTCAE v.3.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="232" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="103" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>DIC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Edema: Limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Edema: Trunk/Genital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Edema: Viscera</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>INR</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Thrombotic microangiopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrhythmia - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Supraventricular arrhythmia, Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>cTnT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Ocular - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="253"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fistula, GI, Abdomen NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fistula, GI, Anus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fistula, GI, Small bowel NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>GI - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Mucositis (functional/symptomatic), Small bowel</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Necrosis, GI, Peritoneal cavity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Obstruction, GI, Colon</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="500"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Obstruction, GI, Ileum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Obstruction, GI, Small bowel NOS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Obstruction, GI, Stomach</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Perforation, GI, Colon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Stricture, GI, Biliary tree</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Ulcer, GI, Duodenum</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional symptoms - Other</sub_title>
                <counts group_id="E1" events="49" subjects_affected="34" subjects_at_risk="500"/>
                <counts group_id="E2" events="39" subjects_affected="23" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term, Disease progression NOS</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="500"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="253"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term, Multi-Organ Failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term, Sudden death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="500"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain, Abdomen NOS</sub_title>
                <counts group_id="E1" events="21" subjects_affected="13" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain, Back</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain, Buttock</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain, Cardiac/Heart</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain, Chest wall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain, Chest/Thorax NOS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain, Extremity - limb</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain, Head/Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain, Joint</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain, Liver</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain, Neuralgia/Peripheral nerve</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain, Pain NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain, Tumor pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Syndromes - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Tumor flare</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hepatobiliary - Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Liver dysfunction</sub_title>
                <counts group_id="E1" events="28" subjects_affected="17" subjects_at_risk="500"/>
                <counts group_id="E2" events="11" subjects_affected="5" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (documented clinically), Abdomen NOS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically), Anal/perianal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically), Appendix</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically), Bladder (urinary)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically), Blood</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically), Bronchus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically), Catheter-related</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically), Kidney</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically), Lung (Pneumonia)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="500"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically), Skin (Cellulitis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically), Soft tissue NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically), Urinary tract NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically), Wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC, Blood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC, Catheter-related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC, Colon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC, Gallbladder (Cholecystitis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC, Kidney</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC, Lung (Pneumonia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC, Soft tissue NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC, Kidney</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC, Lung (Pneumonia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Bilirubin (Hyperbilirubinemia)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="500"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Metabolic/Lab - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Gait/Walking</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Muscle weakness left-sided</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Muscle weakness, Extremity - lower</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Muscle weakness, Whole body/generalized</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Musculoskeletal - Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Secondary malignancy (possibly related to cancer treatment)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>CNS ischemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Mood Alteration, Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neurology - Other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neuropathy: Cranial, CN III Pupil, upper eyelid, extra ocular mov</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neuropathy: motor</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Speech impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Syncope (Fainting)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fistula, GU, Bladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Obstruction, GU, Ureter</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Renal - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="500"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ARDS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dyspnea (Shortness of breath)</sub_title>
                <counts group_id="E1" events="18" subjects_affected="12" subjects_at_risk="500"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pulmonary - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology - Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hand-foot skin reaction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rash/Desquamation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Wound complication, non-infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hemorrhage - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hemorrhage pulmonary, Bronchus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hemorrhage pulmonary, Mediastinum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Abdomen NOS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Anus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Lower GI NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Rectum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Stoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Upper GI NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Varices (esophageal)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Varices (rectal)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GU, Vagina</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Thrombosis/Embolism (vascular access)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Thrombosis/Thrombus/Embolism</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="500"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vascular - Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>NCI-CTCAE v.3.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="489" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="229" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Edema: Limb</sub_title>
                <counts group_id="E1" events="57" subjects_affected="49" subjects_at_risk="500"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="142" subjects_affected="76" subjects_at_risk="500"/>
                <counts group_id="E2" events="46" subjects_affected="29" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="136" subjects_affected="79" subjects_at_risk="500"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="253"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="213" subjects_affected="155" subjects_at_risk="500"/>
                <counts group_id="E2" events="23" subjects_affected="21" subjects_at_risk="253"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="29" subjects_affected="27" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular - Other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="388" subjects_affected="239" subjects_at_risk="500"/>
                <counts group_id="E2" events="96" subjects_affected="73" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="24" subjects_affected="23" subjects_at_risk="500"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="253"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="147" subjects_affected="119" subjects_at_risk="500"/>
                <counts group_id="E2" events="58" subjects_affected="48" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="514" subjects_affected="218" subjects_at_risk="500"/>
                <counts group_id="E2" events="57" subjects_affected="44" subjects_at_risk="253"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fistula, GI, Colon/Cecum/Appendix</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Mucositis (functional/symptomatic), Oral cavity</sub_title>
                <counts group_id="E1" events="267" subjects_affected="145" subjects_at_risk="500"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="162" subjects_affected="115" subjects_at_risk="500"/>
                <counts group_id="E2" events="67" subjects_affected="55" subjects_at_risk="253"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Taste alteration</sub_title>
                <counts group_id="E1" events="44" subjects_affected="39" subjects_at_risk="500"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="144" subjects_affected="85" subjects_at_risk="500"/>
                <counts group_id="E2" events="50" subjects_affected="41" subjects_at_risk="253"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional symptoms - Other</sub_title>
                <counts group_id="E1" events="33" subjects_affected="30" subjects_at_risk="500"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="612" subjects_affected="318" subjects_at_risk="500"/>
                <counts group_id="E2" events="168" subjects_affected="115" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="189" subjects_affected="136" subjects_at_risk="500"/>
                <counts group_id="E2" events="48" subjects_affected="40" subjects_at_risk="253"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Flu-like syndrome</sub_title>
                <counts group_id="E1" events="30" subjects_affected="27" subjects_at_risk="500"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="253"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="43" subjects_affected="39" subjects_at_risk="500"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain, Abdomen NOS</sub_title>
                <counts group_id="E1" events="239" subjects_affected="121" subjects_at_risk="500"/>
                <counts group_id="E2" events="53" subjects_affected="47" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain, Back</sub_title>
                <counts group_id="E1" events="114" subjects_affected="79" subjects_at_risk="500"/>
                <counts group_id="E2" events="27" subjects_affected="25" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain, Buttock</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain, Chest/Thorax NOS</sub_title>
                <counts group_id="E1" events="29" subjects_affected="26" subjects_at_risk="500"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain, Extremity - limb</sub_title>
                <counts group_id="E1" events="83" subjects_affected="51" subjects_at_risk="500"/>
                <counts group_id="E2" events="19" subjects_affected="14" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain, Head/Headache</sub_title>
                <counts group_id="E1" events="65" subjects_affected="50" subjects_at_risk="500"/>
                <counts group_id="E2" events="23" subjects_affected="18" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain, Joint</sub_title>
                <counts group_id="E1" events="34" subjects_affected="32" subjects_at_risk="500"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain, Muscle</sub_title>
                <counts group_id="E1" events="64" subjects_affected="50" subjects_at_risk="500"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain, Throat/Pharynx/Larynx</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="240" subjects_affected="167" subjects_at_risk="500"/>
                <counts group_id="E2" events="34" subjects_affected="30" subjects_at_risk="253"/>
                <counts group_id="E3" events="7" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary - Other</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="500"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="253"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALT</sub_title>
                <counts group_id="E1" events="53" subjects_affected="28" subjects_at_risk="500"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" events="72" subjects_affected="37" subjects_at_risk="500"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="49" subjects_affected="35" subjects_at_risk="500"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Bilirubin (Hyperbilirubinemia)</sub_title>
                <counts group_id="E1" events="160" subjects_affected="97" subjects_at_risk="500"/>
                <counts group_id="E2" events="37" subjects_affected="22" subjects_at_risk="253"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="500"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="253"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>GFR</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="57" subjects_affected="34" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="84" subjects_affected="50" subjects_at_risk="500"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="43" subjects_affected="32" subjects_at_risk="500"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="62" subjects_affected="32" subjects_at_risk="500"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="253"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" events="74" subjects_affected="32" subjects_at_risk="500"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Metabolic/Lab - Other</sub_title>
                <counts group_id="E1" events="69" subjects_affected="42" subjects_at_risk="500"/>
                <counts group_id="E2" events="15" subjects_affected="8" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="109" subjects_affected="40" subjects_at_risk="500"/>
                <counts group_id="E2" events="11" subjects_affected="6" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="31" subjects_affected="28" subjects_at_risk="500"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" events="68" subjects_affected="51" subjects_at_risk="500"/>
                <counts group_id="E2" events="27" subjects_affected="25" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="77" subjects_affected="56" subjects_at_risk="500"/>
                <counts group_id="E2" events="32" subjects_affected="28" subjects_at_risk="253"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dyspnea (Shortness of breath)</sub_title>
                <counts group_id="E1" events="110" subjects_affected="89" subjects_at_risk="500"/>
                <counts group_id="E2" events="46" subjects_affected="34" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Voice changes</sub_title>
                <counts group_id="E1" events="211" subjects_affected="160" subjects_at_risk="500"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="253"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="43" subjects_affected="39" subjects_at_risk="500"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dermatology - Other</sub_title>
                <counts group_id="E1" events="45" subjects_affected="30" subjects_at_risk="500"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="59" subjects_affected="50" subjects_at_risk="500"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hand-foot skin reaction</sub_title>
                <counts group_id="E1" events="720" subjects_affected="235" subjects_at_risk="500"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="253"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="39" subjects_affected="29" subjects_at_risk="500"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rash/Desquamation</sub_title>
                <counts group_id="E1" events="211" subjects_affected="145" subjects_at_risk="500"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="253"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage pulmonary, Nose</sub_title>
                <counts group_id="E1" events="55" subjects_affected="45" subjects_at_risk="500"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="253"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The agreed point of publication is 12-18 months after database lock at the earliest. Bayer will have 30-45 days to review publications, and may request an additional publication delay of up to 60 days to allow for filing a Patent Application (if applicable). No publication of single center data should be done prior of publication if multi-center data.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>At 2nd IA, pre-specified O’Brien-Fleming-type efficacy boundary was crossed. DMC concluded OS result positive and after positive risk benefit assessment, recommended unblinding of study. OS from 2nd IA are the final formal and definitive results.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>BAYER</organization>
      <email>clinical-trials-contact@bayerhealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

